Kite Presents New Data on Yescarta in Relapsed/Refractory Large B-cell Lymphoma at ASH
Kite, a Gilead Company presented new findings from three analyses on Yescarta® (axicabtagene ciloleucel) for relapsed or refractory (R/R) large B-cell lymphoma (LBCL) at the 66th Annual Meeting & Exposition of the American Society of Hematology (ASH). These findings demonstrate…